Today, the majority of drugs and pharmaceuticals on the market that treat human disease are designed to target a specific protein. But University of North Carolina at Chapel Hill startup Ribometrix has a very different, revolutionary approach to new drug discovery that’s proving to be a breakthrough in the industry.